MJ Biotech, Inc., Corporate Update

Cheyenne, WY, Sept. 20, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- (OTC: MJTV) MJ Biotech, Inc. (FKA Michael James Enterprises, Inc.) announces new product lines of CBD Teas and innovative Wellness Products. The premiere MJ BIOTECH product is the MJ CBD Golden Milk, made with ORGANIC TUMERIC, GINGER, CINNAMON and CBD ISOLATE.

The MJ CBD GOLDEN MILK and the new line of CBD Creamers – Powdered - and in-development - a LIQUID form of CBD CREAMERS are very exciting and unique market opportunities for MJ BIOTECH, INC., in addition to the CBD TEA selections, CBD enhanced Oolong, Jasmine and Rooibos.

These products can be seen at  the corporate website  and also at its subsidiaries website .   These new products are being sold through clinics in Florida. 

You may ask what IS CBD??

CBD is "the new 'IT' drug," according to The Washington Post.... Many in the cannabis industry claim that as long as the CBD product contains less than 0.3% THC, it is classified as hemp under Federal law and is, therefore legal to possess and distribute.

CBD may have the potential to treat a wide range of conditions such as anxiety, high blood pressure, skin issues, and chronic pain.

In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD).

CBD is going main stream as confirmed by the following link:

Safe Harbor Statement

This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether because of new information, future events or any other reason.

For additional information please contact via email at